Volume 9, Issue 4 pp. 293-301

Dual vs. Triple Therapy for Childhood Helicobacter pylori Gastritis: a Double-Blind Randomized Multicentre Trial

Giuseppina Oderda

Corresponding Author

Giuseppina Oderda

Pediatric Departments of the Universities of Novara

Reprint requests to: Giuseppina Oderda, Università del Piemonte Orientale, Via Solaroli 17, 28100 Novara, Italy; E-mail: [email protected]Search for more papers by this author
Daniela Marinello

Daniela Marinello

Pediatric Departments of the Universities of Novara

Search for more papers by this author
Pietro LerroMaria KuvidiGian Luigi De’Angelis

Gian Luigi De’Angelis

Parma

Search for more papers by this author
Anna FerzettiSalvatore Cucchiara

Salvatore Cucchiara

Napoli

Search for more papers by this author
Maria Teresa Franco

Maria Teresa Franco

Napoli

Search for more papers by this author
Claudio Romano

Claudio Romano

Reggio Calabria

Search for more papers by this author
Pietro Strisciuglio

Pietro Strisciuglio

Catanzaro, Italy

Search for more papers by this author
Lucia Pensabene

Lucia Pensabene

Catanzaro, Italy

Search for more papers by this author
First published: 16 July 2004
Citations: 26

ABSTRACT

Background. Data on the efficacy of eradication treatment for Helicobacter pylori gastritis in children are scarce.

Aim. To evaluate the efficacy of triple therapy with lansoprazole plus amoxicillin and tinidazole vs. dual therapy with amoxicillin and tinidazole in a double-blind randomized multicentre trial, and the usefulness of eradication in terms of long-term symptom resolution.

Subjects. We enrolled 43 consecutive children undergoing endoscopy for upper gastrointestinal dyspepsia with H. pylori gastritis. They underwent a 13C-urea breath test, completed a 2-week symptom diary card, and were randomized. Treatment was given in a Redidose box (Redidose Company Ltd., Brighton, UK) containing either lansoprazole-amoxicillin-tinidazole (triple therapy) or placebo plus amoxicillin-tinidazole (dual therapy) for 1 week. The completion of a 2-week symptom diary card and the performance of a breath test were repeated 6 weeks and 6 months after the end of therapy. One to two years later, a structured telephone interview was conducted with 36 of the children.

Results. According to the breath test, 6 weeks after the end of therapy H. pylori was eradicated in 15 of 22 children on triple therapy [68.2%; 95% confidence interval (CI) = 45–88] and in 15 of 21 children on dual therapy (71%; 95% CI = 48–89; not significant), and 6 months after the end of therapy it was eradicated in 16 of 22 children on triple therapy (72.7%) and in 15 of 21 children on dual therapy. Six months after therapy, symptoms were analysed in 11 H. pylori-positive and 31 H. pylori-negative children, and it was found that dyspeptic symptoms had disappeared or improved in both groups, with no difference between them. One to two years later, 36 children were interviewed. Epigastric pain had recurred in three of 26 H. pylori-negative and in seven of 10 H. pylori-positive children (p = .001); in three of the latter, pain was severe and required additional treatment.

Conclusion. One-week triple or dual therapy with two antibiotics achieved similar eradication rates. Soon after treatment, symptoms disappeared or improved in most children irrespective of eradication, but epigastric pain recurred in the majority of the still-infected children within 2 years.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.